Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Regulation: ATMP vs minimally manipulated immune cells

Christian Chabannon • 2 Apr 2020
General CAR-T

Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, talks on the regulatory aspects of advanced therapy medicinal products (ATMP) versus minimally manipulated immune cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christian Chabannon

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:33
Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
Christian Chabannon • 17 Feb 2024
1:36
IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma
Christian Chabannon • 21 Oct 2023

Related Videos

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals